Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today that Faraz Ali, Chief Executive Officer, is scheduled to participate in the Chardan 6th Annual Genetic Medicines Conference and the Alliance for Regenerative Medicine’s Cell and Gene Meeting on the Mesa. Details of participation are as follows:
Chardan's 6th Annual Genetic Medicines Conference
Fireside chat
Date: October 4, 2022
Time: 11:00 a.m. ET
A webcast of the Chardan event will be available by visiting the Investors section of Tenaya’s website. A replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.
Alliance for Regenerative Medicine’s Cell and Gene Meeting on the Mesa
Company Presentation
Date: Tuesday, October 11, 2022
Time: 11:45 a.m. PT
Panel: The Future of Gene Delivery: In Search of Game-Changing In Vivo Applications
Date: Thursday, October 13, 2022
Time: 11:00 a.m. – 12:00 p.m. PT
A recording of the Meeting on the Mesa event will be available on the conference platform for on-demand viewing by registered participants.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic cardiovascular disorders, as well as for more prevalent heart conditions, through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit www.tenayatherapeutics.com.
Investors
Michelle Corral
Tenaya Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Wendy Ryan
Ten Bridge Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.46 |
| Daily Change: | 0.0001 0.02 |
| Daily Volume: | 449,667 |
| Market Cap: | US$36.600M |
March 19, 2025 March 10, 2025 March 03, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
